Oral cladribine for acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests an oral (by mouth) form of the chemotherapy drug cladribine, taken daily, for people with AML. It aims to find a safe and effective dose and see how well it controls the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) that has returned or not cleared after treatment, OR you are newly diagnosed and either have a history of MDS treated with certain drugs, or are over 60 with a specific type of AML (monocytic or with a RAS mutation).
- Your liver, kidney, and heart function must be within a safe range (approx. tests to confirm).
- You must be able to swallow capsules or tablets without crushing or breaking them.
- If you are of childbearing age, you must agree to use two forms of birth control during the study and for 90 days after the last dose (both men and women).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (cladribine, low-dose cytarabine, and venetoclax) for people with acute myeloid leukemia (AML) that has come back or hasn't responded to treatment, including those who have previously taken venetoclax. The goal is to see if this combo can help control the leukemia.
This study tests a combination of three drugs—aclarubicin, azacitidine, and venetoclax—for people with acute myeloid leukemia (AML) who cannot have intensive chemotherapy, or whose leukemia has returned after treatment. The goal is to see if this combination helps control the leukemia with manageable side effects.
This Phase 2 study tests a combination chemotherapy plan (cladribine, low-dose cytarabine, and decitabine) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to shrink the leukemia/MDS and improve outcomes, including for certain people who may not tolerate standard treatment.
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
This trial tests an oral drug called PCLX-001 for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and can help control the leukemia.
This Phase 1 trial studies how an oral combination cancer medicine behaves in the body (dose handling and safety) in people with kidney impairment. It may help doctors learn the safest way to use this treatment when kidney function is reduced.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.